U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H19ClN2S.ClH
Molecular Weight 355.325
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORPROMAZINE HYDROCHLORIDE

SMILES

Cl.CN(C)CCCN1C2=C(SC3=C1C=C(Cl)C=C3)C=CC=C2

InChI

InChIKey=FBSMERQALIEGJT-UHFFFAOYSA-N
InChI=1S/C17H19ClN2S.ClH/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20;/h3-4,6-9,12H,5,10-11H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula C17H19ClN2S
Molecular Weight 318.864
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups.

Originator

Curator's Comment: Chlorpromazine was synthesized in December 1951 in the laboratories of Rhône-Poiulenc, and became available on prescription in France in November 1952.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
37.9 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.31 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.9 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
135 ng × h/mL
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
247 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
27.8 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
81.8 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.1 h
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.05 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.48 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9.52 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
unknown, unknown
CHLORPROMAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
75 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 75 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 52 years (range: 36.5-65.6 years)
Health Status: unhealthy
Condition: agitation
Age Group: 52 years (range: 36.5-65.6 years)
Sex: M+F
Sources:
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Other AEs: Adverse event...
25 mg 1 times / day multiple, intramuscular
Dose: 25 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Other AEs: Adverse event...
AEs

AEs

AESignificanceDosePopulation
Adverse event grade 5
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Adverse event grade 5
25 mg 1 times / day multiple, intramuscular
Dose: 25 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Overview

Overview

OverviewOther

Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Deanol in the treatment of tardive dyskinesia.
1975 Aug
[Chronic intrahepatic cholestasis following chlorpromazine; treated using phenobarbital].
1976
The prolongation of QRS-duration resulting from delayed recovery of ventricular excitability. A new mechanism for intraventricular conduction disturbance. A preliminary note.
1976 Nov
Effects of chlorpromazine hydrochloride on bile salt synthesis, bile formation and biliary lipid secretion in the rhesus monkey: a model for chlorpromazine-induced cholestasis.
1979 Feb
A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy.
1992
Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning.
1992 Jul
[A case of neuroleptic malignant syndrome with acute renal failure].
1992 Nov
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
[Intractable vomiting, convulsions and megaloblastic anemia: anamnesis, key to diagnosis].
1999 Jul 3
Tardive dystonia induced by risperidone.
1999 Jun
Effect of some psychotropic drugs and a barbiturate on mycoplasmas.
2000 Apr
Double-blind crossover study of chlorpromazine and lorazepam in the treatment of behavioral problems during treatment of children with acute lymphoblastic leukaemia receiving glucocorticoids.
2000 Apr
Effect of midodrine on chlorpromazine-induced orthostatic hypotension in rabbits: comparison with amezinium, etilefrine and droxidopa.
2000 Dec
Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds.
2000 Jul 28
Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction.
2001 Jan
Chlorpromazine-induced cholestatic liver disease with ductopenia.
2001 Jul
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
2001 Jul
Role of flavonoids in controlling the phototoxicity of Hypericum perforatum extracts.
2001 Jul
Bipolar disorder after mefloquine treatment.
2001 May
Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy.
2001 May
Oral contraceptives increase the plasma concentrations of chlorpromazine.
2001 Oct
Enhanced dendritic cell-driven proliferation and anti-HIV activity of CD8(+) T cells by a new phenothiazine derivative, aminoperazine.
2001 Sep 1
[Ultraviolet spectrophotometric determination of psychotropic drug mixtures].
2002
[Poisonings with psychotropic drug mixtures: analysis using the thin-layer chromatography method].
2002
Effects of chlorpromazine, pentoxifylline and dexamethasone on mRNA expression of lipopolysaccharide-induced inflammatory cytokines in bovine peripheral blood mononuclear cells.
2002 Aug
[Reversal of multidrug resistance in leukemic cell line K562/AO2 by chlordelazine in vitro].
2003 Jul
The antipsychotic drug chlorpromazine inhibits HERG potassium channels.
2003 Jun
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
2003 Mar
Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis.
2003 Mar
Sydenham's chorea may be a risk factor for drug induced parkinsonism.
2003 Sep
UVA activated 8-MOP and chlorpromazine inhibit release of TNF-alpha by post-transcriptional regulation.
2004 Apr
Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors.
2004 Apr 15
Two cases of deep vein thrombosis associated with antipsychotic drug use.
2004 Aug
Smoking impact on CYP1A2 activity in a group of patients with schizophrenia.
2004 Jan
Invited review: fluphenazine augments retinal oxidative stress.
2005 Aug
New inhibitors of the Tat-TAR RNA interaction found with a "fuzzy" pharmacophore model.
2005 Jun
[Thanatogenesis in poisoning with psychopharmaceuticals].
2005 Mar-Apr
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates.
2005 Nov
Effect of chlorpromazine on bone sialoprotein (BSP) gene transcription.
2006 Apr 15
Patents

Sample Use Guides

Usual Adult Dose for Psychosis HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day Usual Adult Dose for Schizophrenia HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day
Route of Administration: Other
In Vitro Use Guide
Chlorpromazine inhibited the serotonin2-mediated excitation of the interneurons of rat piriform cortex with an IC50 of 14 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:12:37 UTC 2023
Edited
by admin
on Fri Dec 15 15:12:37 UTC 2023
Record UNII
9WP59609J6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORPROMAZINE HYDROCHLORIDE
EP   GREEN BOOK   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [JAN]
Common Name English
10-(3-DIMETHYLAMINOPROPYL)-2-CHLOROPHENOTHIAZINE MONOHYDROCHLORIDE
Systematic Name English
CHLORPROMAZINE HYDROCHLORIDE [VANDF]
Common Name English
NCI-C05210
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [USP-RS]
Common Name English
10H-PHENOTHIAZINE-10-PROPANAMINE, 2-CHLORO-N,N-DIMETHYL-, MONOHYDROCHLORIDE
Common Name English
Chlorpromazine hydrochloride [WHO-DD]
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine monohydrochloride
Systematic Name English
CHLORPROMAZINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
CHLORPROMAZINE HCL
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [MART.]
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [EP IMPURITY]
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [GREEN BOOK]
Common Name English
KLORPROMAN
Common Name English
PROMAPAR
Brand Name English
NORCOZINE
Common Name English
SONAZINE
Brand Name English
CHLORPROMAZINE HYDROCHLORIDE [WHO-IP]
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [MI]
Common Name English
MARAZINE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C740
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
EPA PESTICIDE CODE 600006
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
NCI_THESAURUS C29710
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C47975
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
DRUG BANK
DBSALT000026
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
FDA UNII
9WP59609J6
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
CHEBI
3649
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
CAS
69-09-0
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
RS_ITEM_NUM
1125006
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CHLORPROMAZINE HYDROCHLORIDE
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY Description: A white or slightly creamy white, crystalline powder; odour, slight.Solubility: Soluble in 0.4 part of water; freely soluble in ethanol (~750 g/l) TS; practically insoluble in ether R.Category: Neuroleptic.Storage: Chlorpromazine hydrochloride should be kept in a tightly closed container, protected from light.
SMS_ID
100000091060
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
PUBCHEM
6240
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
EPA CompTox
DTXSID7024827
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
EVMPD
SUB01255MIG
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-701-3
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
DAILYMED
9WP59609J6
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
MERCK INDEX
m3461
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY Merck Index
RXCUI
104728
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL71
Created by admin on Fri Dec 15 15:12:37 UTC 2023 , Edited by admin on Fri Dec 15 15:12:37 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY